Cytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum sold 5,000 shares of the stock in a transaction on Friday, September 1st. The shares were sold at an average price of $14.71, for a total value of $73,550.00. Following the completion of the transaction, the chief executive officer now owns 79,785 shares of the company’s stock, valued at $1,173,637.35. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Cytokinetics, Incorporated (NASDAQ CYTK) traded down 0.67% during trading on Friday, hitting $14.75. 307,289 shares of the stock were exchanged. The stock’s market cap is $791.57 million. Cytokinetics, Incorporated has a 52 week low of $8.51 and a 52 week high of $17.20. The stock has a 50 day moving average of $13.45 and a 200-day moving average of $13.28.

Cytokinetics, (NASDAQ:CYTK) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by $0.03. Cytokinetics, had a negative net margin of 16.00% and a negative return on equity of 14.15%. The firm had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $5.28 million. Equities analysts expect that Cytokinetics, Incorporated will post ($2.46) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/01/robert-i-blum-sells-5000-shares-of-cytokinetics-incorporated-cytk-stock.html.

CYTK has been the subject of a number of research reports. Zacks Investment Research upgraded Cytokinetics, from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Monday, August 7th. Cowen and Company reiterated a “buy” rating and issued a $19.00 price target on shares of Cytokinetics, in a research note on Friday, August 4th. HC Wainwright set a $26.00 price objective on Cytokinetics, and gave the company a “buy” rating in a report on Thursday, August 3rd. BidaskClub upgraded Cytokinetics, from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, ValuEngine upgraded Cytokinetics, from a “sell” rating to a “hold” rating in a report on Friday. Three analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $21.30.

Several institutional investors have recently made changes to their positions in the stock. Airain ltd boosted its position in shares of Cytokinetics, by 91.5% in the first quarter. Airain ltd now owns 41,748 shares of the biopharmaceutical company’s stock valued at $536,000 after buying an additional 19,948 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Cytokinetics, during the first quarter worth $802,000. Nine Chapters Capital Management LLC acquired a new stake in shares of Cytokinetics, during the first quarter worth $265,000. Parametric Portfolio Associates LLC boosted its stake in shares of Cytokinetics, by 1.4% in the first quarter. Parametric Portfolio Associates LLC now owns 13,333 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 189 shares during the period. Finally, TFS Capital LLC acquired a new stake in shares of Cytokinetics, during the first quarter worth $1,233,000. Institutional investors own 71.51% of the company’s stock.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Insider Buying and Selling by Quarter for Cytokinetics, (NASDAQ:CYTK)

Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.